Xpamac Inc.

XPAMAC Inc. is a biotechnology startup based in Szeged, Hungary, offering cell line development services for the biotech industry, developing next-generation mammalian cell lines for the efficient, stable, and scalable production of therapeutic proteins. Our proprietary platform built on “Mammalian Elongated Chromosomes”, enables high-yield expression of complex biologics, including monoclonal antibodies and other difficult-to-express proteins. The XPAMAC technology integrates expression cassettes into genomic “safe harbor” regions while allowing control of transgene copy numbers and amplification. This leads to accelerated cell line development, long-term protein expression stability, and significantly increased protein yield compared to traditional gene integration methods. The platform has been successfully validated in CHO-K1, CHO-DG44, and HEK293 cell lines. XPAMAC Inc has 10+ employees and was founded by venture capitalists and distinguished scientists from the Nobel Prize-winning University of Szeged and the HUN-REN Biological Research Centre of Szeged, Hungary. XPAMAC’s multidisciplinary team of scientists and business professionals is committed to supporting partners in overcoming manufacturing bottlenecks in biologics development. The company is actively expanding its international collaborations with biopharma companies and CDMOs partners and aims to become a trusted innovation partner in the evolving biologics manufacturing landscape.